{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:10:18Z","timestamp":1767204618099,"version":"build-2238731810"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018570","name":"Special Project of Central Government for Local Science and Technology Development of Hubei Province","doi-asserted-by":"publisher","award":["2022BGE270"],"award-info":[{"award-number":["2022BGE270"]}],"id":[{"id":"10.13039\/501100018570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2024AFB335, 2024AFB352, 2024AFD434, 2023AFB180"],"award-info":[{"award-number":["2024AFB335, 2024AFB352, 2024AFD434, 2023AFB180"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Renal squamous cell carcinoma (RSCC) is an uncommon malignancy, representing less than 1% of all renal cancers, and is associated with a notably poor prognosis. Surgical intervention is the primary treatment modality for early and intermediate-stage cases; however, the efficacy of combined chemoradiotherapy and immunotherapy in advanced-stage patients remains unclear. In this report, we present a case of RSCC with pulmonary metastases, wherein the patient attained disease remission following a treatment regimen comprising combined chemo-radiotherapy and immunotherapy. The patient demonstrated a progression-free survival (PFS) of 12 months and an overall survival (OS) of 14 months. This case study aims to provide a comprehensive analysis of the treatment approach, potentially serving as a reference for therapeutic strategies in patients with inoperable RSCC.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1645909","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T05:28:22Z","timestamp":1754630902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanlin","family":"Niu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinzhou","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part a: Renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.15586\/jkcvhl.v10i3.295","article-title":"Systemic treatment for advanced and metastatic non-clear cell renal cell carcinoma: Examining modern therapeutic strategies for a notoriously challenging Malignancy","volume":"10","author":"Drobner","year":"2023","journal-title":"J Kidney Cancer VHL"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.09.010","article-title":"Upper urinary tract tumors with nontransitional histology: a single-center experience","volume":"67","author":"Busby","year":"2006","journal-title":"Urology"},{"key":"B4","first-page":"197","article-title":"A histomorphologic and ultrastructural study of the Malignant tumours of the renal pelvis","volume":"39","author":"Tyagi","year":"1993","journal-title":"J Postgrad Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2020.04.005","article-title":"Imaging for metastatic renal cell carcinoma","volume":"47","author":"Vig","year":"2020","journal-title":"Urol Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010070","article-title":"Navigating the current landscape of non-clear cell renal cell carcinoma: A review of the literature","volume":"30","author":"John","year":"2023","journal-title":"Curr Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153807","article-title":"Characteristics and treatment challenges of non-clear cell renal cell carcinoma","volume":"13","author":"Sepe","year":"2021","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini","year":"2019","journal-title":"J immunotherapy Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/256813","article-title":"Primary intraparenchymal squamous cell carcinoma of the kidney: a rare and unique entity","volume":"2014","author":"Ghosh","year":"2014","journal-title":"Case Rep Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.5489\/cuaj.2441","article-title":"Renal calculus complicated with squamous cell carcinoma of renal pelvis: Report of two cases","volume":"9","author":"Xiao","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01723-7","article-title":"Recent advances in preclinical models for lung squamous cell carcinoma","volume":"40","author":"Pan","year":"2021","journal-title":"Oncogene"},{"key":"B14","article-title":"Squamous cell lung cancer","volume-title":"StatPearls","author":"Sabbula","year":"2025"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e14310","DOI":"10.1097\/MD.0000000000014310","article-title":"Solitary renal metastasis from squamous cell carcinoma of the lung: a case report","volume":"98","author":"Wang","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2022.11.132","article-title":"Renal metastasis from lung squamous-cell carcinoma: a case report","volume":"46","author":"Wu","year":"2023","journal-title":"Asian J Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09771.x","article-title":"Solitary, isolated metastatic disease to the kidney: memorial sloan-kettering cancer center experience","volume":"108","author":"Adamy","year":"2011","journal-title":"BJU Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.46883\/2023.25920997","article-title":"Squamous cell carcinoma of the kidney: A large case series","volume":"37","author":"Sas","year":"2023","journal-title":"Oncol (willist Park NY)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.019","article-title":"Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies","volume":"61","author":"Ni","year":"2012","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.033","article-title":"Squamous cell carcinoma of the renal pelvis and ureter: Incidence, symptoms, treatment and outcome","volume":"178","author":"Holm\u00e4ng","year":"2007","journal-title":"J Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2011.08.009","article-title":"Squamous cell carcinoma of the renal pelvis","volume":"16","author":"Bhaijee","year":"2012","journal-title":"Ann Diagn Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01692-z","article-title":"A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: Interim analysis of Japanese real-world data","volume":"25","author":"Hinata","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clgc.2020.05.006","article-title":"Safety and efficacy of nivolumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase IIIb\/IV CheckMate 374 study","volume":"18","author":"Vogelzang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.1891","article-title":"First-line therapy for advanced non\u2013clear cell renal cell carcinoma: A systematic review and meta-analysis","author":"Petrelli","year":"2025","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3233\/KCA-210012","article-title":"A systematic review of immune checkpoint inhibitors in non-clear-cell renal cancer","volume":"6","author":"Palma Dos Reis","year":"2022","journal-title":"Kidney Cancer (clifton Va)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0475","article-title":"The clinical activity of PD-1\/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma","volume":"6","author":"McKay","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0372","article-title":"Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institutional experience and literature meta-analysis","volume":"25","author":"Chahoud","year":"2020","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.581189","article-title":"Outcomes with first-line PD-1\/PD-L1 inhibitor monotherapy for metastatic renal cell carcinoma (mRCC): A multi-institutional cohort","volume":"10","author":"Barata","year":"2020","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174353","article-title":"Advanced non-clear cell renal cell carcinoma treatments and survival: A real-world single-centre experience","volume":"15","author":"Bimbatti","year":"2023","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ (clin Res Ed)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1478245","article-title":"Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: A systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12672-023-00641-2","article-title":"Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC","volume":"14","author":"Yi","year":"2023","journal-title":"Discov Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa021","article-title":"Association between PD-L1 status and immune checkpoint inhibitor response in advanced Malignancies: a systematic review and meta-analysis of overall survival data","volume":"50","author":"Wallis","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15981","article-title":"Adjuvant immunotherapy in renal cell carcinoma: A systematic review and meta-analysis","volume":"131","author":"Riveros","year":"2023","journal-title":"BJU Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features","volume":"38","author":"McGregor","year":"2020","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110802","article-title":"Response evaluation and tumor shrinkage pattern post-SBRT for renal cell carcinoma","volume":"206","author":"Cai","year":"2025","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/1533033818822329","article-title":"Renal cancer is not radioresistant: Slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy","volume":"18","author":"Funayama","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100909","article-title":"A patient-level data meta-analysis of the abscopal effect","volume":"7","author":"Hatten","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic review of case reports on the abscopal effect","volume":"40","author":"Abuodeh","year":"2016","journal-title":"Curr Probl Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2174\/1389450121666200311121540","article-title":"Immunotherapy and radiation therapy in renal cell carcinoma","volume":"21","author":"Mollica","year":"2020","journal-title":"Curr Drug Targets"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4190","article-title":"PD-1\/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies","volume":"10","author":"Ding","year":"2021","journal-title":"Cancer Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.06.001","article-title":"Nab-paclitaxel: A flattering facelift","volume":"92","author":"Vi\u00fadez","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J Controlled Release"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54487","article-title":"Nephrological detrimental impacts resulting from novel immunotherapy drugs used in the treatment of cancer: A systematic review","volume":"16","author":"Jaiswal","year":"2024","journal-title":"Cureus"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: Incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v13.i4.100037","article-title":"Primary parenchymal squamous cell carcinoma of the kidney: A case report","volume":"13","author":"Zheng","year":"2025","journal-title":"World J Clin cases"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1037156","article-title":"Primary squamous cell carcinoma of renal parenchyma: a case report and literature review","volume":"13","author":"Liang","year":"2023","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2022.102283","article-title":"Full of twists and turns: Collecting duct carcinoma presenting as persistent cough","volume":"45","author":"Li","year":"2022","journal-title":"Urol Case Rep"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1751999","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1645909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:29:10Z","timestamp":1764329350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1645909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2025.1645909"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1645909","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"1645909"}}